FemHealth Ventures

Fogarty Innovation is a nonprofit organization established in 2007 and based in Mountain View, California, focused on advancing medical innovation to enhance human health. The organization supports promising innovators and researchers in transforming creative ideas into practical solutions for patient care. It provides mentorship and educational resources throughout the innovation process, facilitating access to intellectual, physical, and financial tools necessary to advance medical concepts from initiation to application. Fogarty Innovation operates two main programs: one that fosters innovation for startups and another aimed at educating the next generation of inventors. Through these initiatives, it aims to propel research and development in the medical field.

Raydiant Oximetry, Inc. is a medical device company founded in 2015 and headquartered in Mountain View, California. The company focuses on improving childbirth outcomes for mothers and infants by developing a low-cost, non-invasive device that monitors fetal oxygen levels during labor. This innovative technology aims to provide real-time insights into fetal oxygenation, which can help clinicians make informed decisions and reduce the risks associated with childbirth, such as birth injuries and unnecessary cesarean sections. By enhancing patient care and potentially lowering healthcare costs, Raydiant Oximetry's device addresses critical needs in maternal and fetal health.

Nymbl Science training helps maintain and improve balance for a better quality of life, at every age. The company's mission is to use medical science and mobile technology to improve balance and prevent falls. Nymbl is a scientifically validated digital balance training program that will prevent 1 million falls. It’s an effective and engaging way to train the brain and body to work together, using just a smartphone and in only 10 minutes a day, allowing older adults to preserve and enhance their freedom and enjoyment of life.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.